Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.86 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.51 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.51 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081964 | 0.95 | KDR (0.81) | KDRCHEK1PDGFRBPDGFRALYN | |
| SCHEMBL5141013 | 0.94 | KDR (0.77) | KDRCHEK1PDGFRBPDGFRAKDM4E | |
| SCHEMBL5081995 | 0.93 | KDR (1.00) | KDRCHEK1PDGFRBPDGFRATNKS | |
| SCHEMBL29460356 | 0.93 | KDR (1.00) | KDRCHEK1PDGFRBPDGFRATNKS | |
| SCHEMBL5078793 | 0.92 | KDR (0.75) | KDRCHEK1PDGFRBPDGFRAKDM4E | |
| SCHEMBL5081988 | 0.92 | KDR (0.77) | KDRCHEK1PDGFRBPDGFRAKDM4E | |
| SCHEMBL5079376 | 0.90 | KDR (0.74) | KDRCHEK1PDGFRBPDGFRALYN | |
| SCHEMBL5078715 | 0.89 | KDR (0.72) | KDRCHEK1PDGFRBPDGFRAKDM4E | |
| SCHEMBL5082008 | 0.89 | KDR (0.72) | KDRCHEK1PDGFRBPDGFRAKDM4E | |
| SCHEMBL5078729 | 0.89 | KDR (0.72) | KDRCHEK1PDGFRBPDGFRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | claimed |
| US-20080274107-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2008-11-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050096344-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2005-05-05 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096344-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885PDGFRB 88/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | KDR 318/4885CHEK1 3711/4885PDGFRB 421/4885 |
| US-20080274107-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885PDGFRB 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.